Willow Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Willow Biosciences has a total shareholder equity of CA$3.4M and total debt of CA$676.0K, which brings its debt-to-equity ratio to 19.7%. Its total assets and total liabilities are CA$6.7M and CA$3.2M respectively.
Key information
19.7%
Debt to equity ratio
CA$676.00k
Debt
Interest coverage ratio | n/a |
Cash | CA$3.78m |
Equity | CA$3.44m |
Total liabilities | CA$3.24m |
Total assets | CA$6.67m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 3D7's short term assets (CA$4.2M) exceed its short term liabilities (CA$1.8M).
Long Term Liabilities: 3D7's short term assets (CA$4.2M) exceed its long term liabilities (CA$1.4M).
Debt to Equity History and Analysis
Debt Level: 3D7 has more cash than its total debt.
Reducing Debt: 3D7's debt to equity ratio has increased from 0% to 19.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3D7 has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 3D7 is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.